In the current paper, we not only confirm our previous results, demonstrating the therapeutic efficacy of combining MP-based delivery systems with FGF1 or NRG1 in a pig MI model24, 25, 26, but also further demonstrate for the first time the feasibility of MPs as an injectable material for treating MI through minimally invasive approaches, proving its potential for clinical application. The gene discussed is FGF1; the disease is myocardial infarction.